Figure 4
From: Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model
Rapamycin do not salvage severe influenza progressive under Oseltamivir. High (3 mg/kg bodyweight) and low (0.03 mg/kg bodyweight) dose salvage Rapamycin treatment accelerates disease progression and abolishes protective effect of Oseltamivir treatment, regardless of timing of treatment. Naïve BALB/c mice of comparable age were infected with either (a) 2.5 × 103 PFU or (b) 1.25 × 104 PFU PR8 influenza virus. Rapamycin and Oseltamivir treatment was started from the stated days post infection and control untreated mice received daily intraperitoneal injection of equal volume placebo solvent and oral feeding of phosphate buffered solution (PBS). Mice with Oseltamivir only served as another control group. Data are representative of at least three similar experiments and presented as mean ± s.d. (***p < 0.0001; **p < 0.001; *p < 0.01; NS = non-significant, p > 0.05; n = 6/group).
